|
1
|
Alter MJ: Epidemiology of hepatitis C
virus infection. World J Gastroenterol. 13:2436–2441. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lavanchy D: The global burden of hepatitis
C. Liver Int. 29:74–81. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mohd Hanafiah K, Groeger J, Flaxman AD and
Wiersma ST: Global epidemiology of hepatitis C virus infection: New
estimates of age-specific antibody to HCV seroprevalence.
Hepatology. 57:1333–1342. 2013. View Article : Google Scholar
|
|
4
|
Zhu Y and Chen S: Antiviral treatment of
hepatitis C virus infection and factors affecting efficacy. World J
Gastroenterol. 19:8963–8973. 2013. View Article : Google Scholar :
|
|
5
|
Sarasin-Filipowicz M: Interferon therapy
of hepatitis C: molecular insights into success and failure. Swiss
Med Wkly. 140:3–11. 2010.
|
|
6
|
Feld JJ: The beginning of the end: what is
the future of interferon therapy for chronic hepatitis C? Antiviral
Res. 105:32–38. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Poordad F, McCone J Jr, Bacon BR, et al:
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J
Med. 364:1195–1206. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jacobson IM, McHutchison JG, Dusheiko G,
et al: Telaprevir for previously untreated chronic hepatitis C
virus infection. N Engl J Med. 364:2405–2416. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gane EJ, Stedman CA, Hyland RH, et al:
Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for
hepatitis C. N Engl J Med. 368:34–44. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lawitz E, Mangia A, Wyles D, et al:
Sofosbuvir for previously untreated chronic hepatitis C infection.
N Engl J Med. 368:1878–1887. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pawlotsky JM: Treatment failure and
resistance with direct-acting antiviral drugs against hepatitis C
virus. Hepatology. 53:1742–1751. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wyles DL: Beyond telaprevir and
boceprevir: resistance and new agents for hepatitis C virus
infection. Top Antivir Med. 20:139–145. 2012.PubMed/NCBI
|
|
13
|
Fire A, Xu S, Montgomery MK, Kostas SA,
Driver SE and Mello CC: Potent and specific genetic interference by
double-stranded RNA in Caenorhabditis elegans. Nature. 391:806–811.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fire A: RNA-triggered gene silencing.
Trends Genet. 15:358–363. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Carthew RW and Sontheimer EJ: Origins and
mechanisms of miRNAs and siRNAs. Cell. 136:642–655. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huntzinger E and Izaurralde E: Gene
silencing by microRNAs: contributions of translational repression
and mRNA decay. Nat Rev Genet. 12:99–110. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kawamata T and Tomari Y: Making RISC.
Trends Biochem Sci. 35:368–376. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cullen BR: Transcription and processing of
human microRNA precursors. Mol Cell. 16:861–865. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yi R, Qin Y, Macara IG and Cullen BR:
Exportin-5 mediates the nuclear export of pre-microRNAs and short
hairpin RNAs. Genes Dev. 17:3011–3016. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sontheimer EJ: Assembly and function of
RNA silencing complexes. Nat Rev Mol Cell Biol. 6:127–138. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zeng Y, Wagner EJ and Cullen BR: Both
natural and designed microRNAs can inhibit the expression of
cognate mRNAs when expressed in human cells. Mol Cell. 9:1327–1333.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Baumann V and Winkler J: miRNA-based
therapies: Strategies and delivery platforms for oligonucleotide
and non-oligonucleotide agents. Future Med Chem. 6:1967–1984. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fukutomi T, Zhou Y, Kawai S, Eguchi H,
Wands JR and Li J: Hepatitis C virus core protein stimulates
hepatocyte growth: correlation with upregulation of wnt-1
expression. Hepatology. 41:1096–1105. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Boulant S, Douglas MW, Moody L, Budkowska
A, Targett-Adams P and McLauchlan J: Hepatitis C virus core protein
induces lipid droplet redistribution in a microtubule- and
dynein-dependent manner. Traffic. 9:1268–1282. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sato Y, Kato J, Takimoto R, et al:
Hepatitis C virus core protein promotes proliferation of human
hepatoma cells through enhancement of transforming growth factor α
expression via activation of nuclear factor-κB. Gut. 55:1801–1808.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Park J, Kang W, Ryu SW, et al: Hepatitis C
virus infection enhances TNF-α-induced cell death via suppression
of nuclear factor-κB. Hepatology. 56:831–840. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lerat H, Honda M, Beard MR, et al:
Steatosis and liver cancer in transgenic mice expressing the
structural and nonstructural proteins of hepatitis C virus.
Gastroenterology. 122:352–365. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Moriya K, Fujie H, Shintani Y, et al: The
core protein of hepatitis C virus induce hepatocellular carcinoma
in transgenic mice. Nat Med. 4:1065–1067. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Neveu G, Barouch-Bentov R, Ziv-Av A,
Gerber D, Jacob Y and Einav S: Identification and targeting of an
interaction between a tyrosine motif within hepatitis C virus core
protein and AP2M1 essential for viral assembly. PLoS Pathog.
8:e10028452012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Egger D, Wölk B, Gosert R, Bianchi L, Blum
HE, Moradpour D and Bienz K: Expression of hepatitis C virus
proteins induces distinct membrane alterations including a
candidate viral replication complex. J Virol. 76:5974–5984. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hügle T, Fehrmann F, Bieck E, et al: The
hepatitis C virus nonstructural protein 4B is an integral
endoplasmic reticulum membrane protein. Virology. 284:70–81. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gosert R, Egger D, Lohmann V,
Bartenschlager R, Blum HE, Bien K and Moradpour D: Identification
of the hepatitis C virus RNA replication complex in Huh7 cells
harboring subgenomic replicons. J Virol. 77:5487–5492. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Einav S, Elazar M, Danieli T and Glenn JS:
A nucleotide binding motif in hepatitis C virus (HCV) NS4B mediates
HCV RNA replication. J Virol. 78:11288–11295. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Thompson AA, Zou A, Yan J, et al:
Biochemical characterization of recombinant hepatitis C virus
nonstructural protein 4B: evidence for ATP/GTP hydrolysis and
adenylate kinase activity. Biochemistry. 48:906–916. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Einav S, Gerber D, Bryson PD, et al:
Discovery of a hepatitis C target and its pharmacological
inhibitors by microfluidic affinity analysis. Nat Biotechnol.
26:1019–1027. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Han Q, Manna D, Belton K, Cole R and Konan
KV: Modulation of hepatitis C virus genome encapsidation by
nonstructural protein 4B. J Virol. 87:7409–7422. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jones DM, Patel AH, Targett-Adams P and
McLauchlan J: The hepatitis C virus NS4B protein can
trans-complement viral RNA replication and modulates production of
infectious virus. J Virol. 83:2163–2177. 2009. View Article : Google Scholar :
|
|
38
|
Davidson BL and McCray PB Jr: Current
prospects for RNA interference-based therapies. Nat Rev Genet.
12:329–340. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tang H and Grisé H: Cellular and molecular
biology of HCV infection and hepatitis. Clin Sci (Lond). 117:49–65.
2009. View Article : Google Scholar
|
|
40
|
Arbuthnot P: Harnessing RNA interference
for the treatment of viral infections. Drug News Perspect.
23:341–350. 2010.PubMed/NCBI
|
|
41
|
Zhou J and Rossi JJ: Progress in
RNAi-based antiviral therapeutics. Methods Mol Biol. 721:67–75.
2011.PubMed/NCBI
|
|
42
|
Khaliq S, Jahan S, Ijaz B, et al:
Inhibition of core gene of HCV 3a genotype using synthetic and
vector derived siRNAs. Virol J. 7:3182010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ali Ashfaq U, Ansar M, Sarwar MT, Javed T,
Rehman S and Riazuddin S: Post-transcriptional inhibition of
hepatitis C virus replication through small interference RNA. Virol
J. 8:1122011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
DeVincenzo JP: The promise, pitfalls and
progress of RNA-interference-based antiviral therapy for
respiratory viruses. Antivir Ther. 17(1 Pt B): 213–225. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhang R and Su B: Small but influential:
the role of microRNAs on gene regulatory network and 3′UTR
evolution. J Genet Genomics. 36:1–6. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Pillai RS, Bhattacharyya SN, Artus CG, et
al: Inhibition of translational initiation by Let-7 MicroRNA in
human cells. Science. 309:1573–1576. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Shukla GC, Singh J and Barik S: MicroRNAs:
processing, maturation, target recognition and regulatory
functions. Mol Cell Pharmacol. 3:83–92. 2011.PubMed/NCBI
|
|
49
|
Boulant S, Vanbelle C, Ebel C, Penin F and
Lavergne JP: Hepatitis C virus core protein is a dimeric
alpha-helical protein exhibiting membrane protein features. J
Virol. 79:11353–11365. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Boulant S, Montserret R, Hope RG, et al:
Structural determinants that target the hepatitis C virus core
protein to lipid droplets. J Biol Chem. 281:22236–22247. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Moriya K, Nakagawa K, Santa T, et al:
Oxidative stress in the absence of inflammation in a mouse model
for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res.
61:4365–4370. 2001.PubMed/NCBI
|
|
52
|
Dvory-Sobol H, Pang PS and Glenn JS: The
future of HCV therapy: NS4B as an antiviral target. Viruses.
2:2481–2492. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Gouttenoire J, Penin F and Moradpour D:
Hepatitis C virus nonstructural protein 4B: a journey into
unexplored territory. Rev Med Virol. 20:117–129. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Rai R and Deval J: New opportunities in
anti-hepatitis C virus drug discovery: targeting NS4B. Antiviral
Res. 90:93–101. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Lin C, Wu JW, Hsiao K and Su MS: The
hepatitis C virus NS4A protein: interactions with the NS4B and NS5A
proteins. J Virol. 71:6465–6471. 1997.PubMed/NCBI
|
|
56
|
Gouttenoire J, Montserret R, Kennel A,
Penin F and Moradpour D: An amphipathic α-helix at the C terminus
of hepatitis C virus nonstructural protein 4B mediates membrane
association. J Virol. 83:11378–11384. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Israsena N, Supavonwong P, Ratanasetyuth
N, Khawplod P and Hemachudha T: Inhibition of rabies virus
replication by multiple artificial microRNAs. Antiviral Res.
84:76–83. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Ibrišimović M, Kneidinger D, Lion T and
Klein R: An adenoviral vector-based expression and delivery system
for the inhibition of wild-type adenovirus replication by
artificial microRNAs. Antiviral Res. 97:10–23. 2013. View Article : Google Scholar
|
|
59
|
Kato K, Senoki T and Takaku H: Inhibition
of HIV-1 replication by RNA with a microRNA-like function. Int J
Mol Med. 31:252–258. 2013.
|
|
60
|
Yang X, Haurigot V, Zhou S, Luo G and
Couto LB: Inhibition of hepatitis C virus replication using
adeno-associated virus vector delivery of an exogenous
anti-hepatitis C virus microRNA cluster. Hepatology. 52:1877–1887.
2010. View Article : Google Scholar : PubMed/NCBI
|
